Fig. 3

The PFS of patients treated with everolimus combined with endocrine therapy stratified by primary resistance or nonprimary resistance to drugs used in previous treatments. A total of 120 patients received everolimus; 19 patients received drugs to which they acquired primary resistance during previous treatment (blue); 20 patients received drugs to which they acquired nonprimary resistance during previous treatment (red); and 81 patients received drugs that were not previously used (green). PFS, progression-free survival